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Breast cancer represents a significant public health burden globally, representing the most frequently 
diagnosed cancer among females. Within South Africa, female breast cancer accounts for 21.46% of 
all cancers. This has an impact on public health resources including hospital visits, treatment costs, 
and long-term morbidities. Upper limb pain and disability occur as a result of breast cancer treatments 
including surgery, radiotherapy and chemotherapy. This morbidity presents soon after treatment, 
persists into the long-term and may result in the need for post-treatment rehabilitation and an 
inability to return to work.  
 
This dissertation addresses the prevalence and predictors of shoulder morbidity in women in Cape 
Town, South Africa, post- treatment for breast cancer.  
 
Part A is the study protocol, summarising the aims, methodology and ethical considerations for the 
study, including a rationale for its importance.   
 
Part B is a structured literature review summarising pertinent research in the field, providing context 
for the dissertation and subsequent analysis.  
 
Part C is a journal-ready manuscript prepared for submission to the journal Acta Oncologica. This 
summarises the methodology, results and interpretation of the key findings of the analysis conducted. 
 
The results showed that 75% of patients studied experienced some degree of pain or disability post-
treatment for breast cancer. Multivariable ordinal logistic regression analysis identified race, side, 
axillary surgery, chemotherapy and age as significant predictors of pain, and chemotherapy a 
significant predictor of disability. This burden of disease many years after treatment represents a 
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significant public health burden for South Africa. Using pre-identified clinical and demographic 
characteristics may guide in the development of survivorship programmes incorporating surveillance 
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To determine the prevalence of shoulder morbidity in women treated for breast cancer at a tertiary 





Breast cancer incidence  
 
Globally, breast cancer is the most frequently diagnosed cancer and leading cause of cancer death 
among females in both low-to-middle income countries (LMICs) and high-income countries (HICs) (Jemal 
et al. 2011). Estimates from 2008 report that 23% of the total cancer cases and 14% of the cancer 
death is attributed to breast cancer with approximately 50% of the cases and 60% of the deaths 
occurring in LMICs (Jemal et al. 2011). Globally, the age-standardized rate of breast cancer per 100,000 
is 27.3% for LMICs countries compared to 66.4% for HICs (Jemal et al. 2011). In LMICs, it is associated 
with a lower cumulative mortality risk (0-74 years) of 1.2% compared to 9% for all cancers (Jemal et 
al. 2011).  
 
This disease represents a considerable public health burden in South Africa (Herbst 2016). Although 
rare in men, breast cancer accounts for 0.45% of all male cancers (National Health Laboratory Service 
2011).   Data from the South African National Cancer Registry reports an increased incidence of breast 
cancer for women in 2011 of 6849 per 100 000 per year , compared to 6125 and 5280 per 100 000 per 
year in 2010 and 2000, respectively (Herbst 2016; National Health Laboratory Service 2011). When 
breaking down the statistics, the incidence of 6849 represents 21.46% of all cancers in females, with 
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a cumulative lifetime incidence risk (0-74 years) of 3.51% and a lifetime risk of 1 in 29 females 
developing breast cancer (National Health Laboratory Service 2011).  
 
More specifically, the greatest incidence of breast cancer in females occurs between the ages of 45-
64 years, and can occur as young as between 10-14 years old and as old as 85 years (National Health 
Laboratory Service 2011). When broken down according to race, breast cancer accounts for 20.87% 
of cancers in Black African females, 35.44% in Asian females, 26.63% in mixed ancestry female, and 
19.89% in Caucasian females (National Health Laboratory Service 2011). 
 
In high-income countries, mortality rates from breast cancer have declined over time, with a resultant 
improvement in survival rates from 10% in 1970 to about 40% for women treated after 1995 (Tosello 
et al. 2014). Recent data in 2012 from the International Cancer Research group, Globocan, estimate 
incidence, mortality and 5-year prevalence of breast cancer in women for the World Health 
Organization Africa Region (WHO AFRO) as 26.2%, 19.6% and 35.5%, respectively (International 
Agency for Research on Cancer (IARC) n.d.) Within the South African Republic, estimates are similar to 
the WHO AFRO data with incidence, mortality and 5-year prevalence of 24.5%, 15.9% and 34.3%, 
respectively (International Agency for Research on Cancer (IARC) n.d.).  When breast cancer is 
diagnosed and treated early, cure is often possible (UpToDate n.d.). Where implemented, screening 
programmes, early diagnosis and new treatments have resulted in a decline in mortality (UpToDate 
n.d.). However, these remain challenges for LMICs such as South Africa, where many patients present 
with advanced disease and there is a lack of access to newest treatment options that may be available 
in HICs (Mutebi & Edge 2014; Marcus et al. 2013).  
 
The medical management of breast cancer includes surgery, radiation, chemotherapy, biological 
agents, endocrine (hormonal) therapy, and/or a combination of these (Tosello et al. 2014). There are 
several surgical options including radical mastectomy (removal of the breast, lymph nodes and 
4 | P a g e  
 
adjacent muscular tissue), modified radical mastectomy (removal of entire breast including axillary 
lymph nodes but not the muscular tissue) and breast conserving surgery (BCT) (Cotlar et al. 2003). BCT 
or breast conservation is also known as wide local excision (WLE) or partial mastectomy, and may 
include a lumpectomy whereby only the tumour and a margin of breast around the tumour is removed 
(UpToDate n.d.). Breast cancer treatment may result in patients surviving long-term and many 
experience long-term side effects as a result of the different treatment modalities. Furthermore, many 
receive a combination of treatments and thus may develop multiple issues (Shamley 2015). 
 
Post-treatment Morbidity  
 
These side effects include decreased sexuality and fertility, cardiovascular disease secondary to 
treatment, decreased bone health, lymphoedema, increased risk of second primary malignancies, and 
thromboembolic risk (Bodai & Tuso 2015).  Additionally, bilateral upper limb pain and dysfunction is a 
common complication after treatment for breast cancer and can present immediately after treatment 
or up to six years later (Bodai & Tuso 2015; Hidding et al. 2014; Shamley et al. 2012)  
 
Shoulder morbidity comprises decreased shoulder complex mobility, pain and numbness, tightness, 
oedema, and weakness. This may also include emotional distress resulting in isolation and can affect 
activities of daily living (ADL) including the ability to return to work (Shamley 2015).  Although the 
mechanism for this is poorly understood, altered musculo-skeletal function affects the ability to move 
and results in reduced range of motion (ROM) and chronic pain (Shamley et al. 2012; Shamley 2015).  
 
Therefore, research now includes evaluation of mechanics and genomics in order to better understand 
the aetiology (Shamley 2015). Reduced ROM, pain and lymphoedema are the most commonly 
described shoulder morbidities (Hidding et al. 2014).  A systematic review evaluating the impairment 
in functions and structures in the upper extremity and upper body found that in women who received 
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curative treatment interventions, the most significant of these was with axillary lymph node dissection 
(ALND) (Hidding et al. 2014). Treatments evaluated included surgery (mastectomy, lumpectomy, 
ALND, sentinel node biopsy (SNB), and breast reconstruction), radiotherapy, chemotherapy and 
hormonal therapy and outcomes assessed were reduced ROM, reduced muscle strength, pain, 
lymphoedema and decreased degree of ADL  (Hidding et al. 2014). 
 
The incidence of reduced ROM varies according to study design and length of follow up, however, 
reduced ROM occurs between 1%-67% of patients (Hidding et al. 2014). Risk factors include greater 
number of lymph nodes removed, cording (palpable cords in the axillary region that develop as a side 
effect of surgery), mastectomy, stage II breast cancer, side of hand dominance, and increased BMI and 
age (Hidding et al. 2014; Bodai & Tuso 2015). Age is also a contributory factor to limitation in ADL, as 
well as ALND, radiotherapy and the presence of other comorbidities (Hidding et al. 2014).  Reduced 
ROM develops in the first month post-operatively and appears to decrease with time (Hidding et al. 
2014). 
 
Contrastingly, breast cancer-related lymphoedema seems to increase over time, with a higher 
incidence after one month. Lymphoedema is a chronic, incurable and debilitating side effect of breast 
cancer treatment and occurs in up to 34% of patients (Hidding et al. 2014).  Risk factors for 
lymphoedema include ALND, radical mastectomy, radiotherapy and chemotherapy (Hidding et al. 
2014).   
 
Pain occurs between 8%-68% of patients and reduction in muscle strength between 17%-72% of 
patients, with evidence suggesting that pain and dysfunction may last as long as up to 6 years (Hidding 
et al. 2014).  Movement patterns are different for left versus right-sided affected, with the left side 
affected associated with greater levels of pain and dysfunction (Shamley et al. 2012). Moreover, the 
addition of chemotherapy further contributes to the difference seen between the affected and 
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unaffected sides (Shamley et al. 2012). Acute and chronic pain appear to have a different set of risk 
factors; anxiety for acute post-operative pain, and more invasive surgery (mastectomy as opposed to 
WLE), radiotherapy and acute post-operative pain for chronic post-operative pain (Shamley et al. 
2009) (Shamley et al. 2012). Connective tissue changes such as scarring and cording are also known 
contributory factors to arm dysfunction and pain after treatment. (Hidding et al. 2014).   
 
A way to quantify these adverse events is to use patient-reported outcomes, with the aid of a validated 
questionnaire in order to establish the presence of pain and disability. A self-reported outcome 
measure is considered preferable over the use of ascertaining ROM when evaluating treatment 
effectiveness for clinical and research use (Williams et al. 1995).  
 
Shoulder Morbidity Questionnaires  
 
There are several self-reported shoulder disability questionnaires, including the Disabilities of the Arm, 
Shoulder, and Hand (DASH), Shoulder Pain and Disability Index (SPADI), the American Shoulder and 
Elbow Surgeons (ASES) score, the Shoulder Rating Questionnaire (SRQ) and the Simple Shoulder Test 
(SST) (Roy et al. 2009).  There is currently no gold standard for measuring shoulder pain and disability. 
SPADI is often a preferred questionnaire for assessing shoulder problems presenting in primary care 
due to its validity, responsiveness to change, and acceptability. However, the decision for which 
questionnaire to use will be guided by the type of study and the practical considerations required (Paul 
et al. 2004).  
 
The Shoulder Pain and Disability Index (SPADI) questionnaire is a reliable and valid measure of pain 
and disability for shoulder dysfunction (Roy et al. 2009). The scale is a visual analogue scale (VAS) of 
13 items (5 for pain and 8 for disability). Scores for pain range from a minimum of 0 cm to a maximum 
of 50 cm and for disability 0-80 cm. Patients are asked to range their answers between 0 and 10, with 
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0 representing no symptoms of pain or disability and 10 representing the worst pain imaginable and 
a need for help due to disability (Shamley et al. 2009).  The VAS has been shown to have high reliability 
and concurrent validity and takes on average 5-20 minutes to complete (Roy et al. 2009; Breckenridge 
& McAuley 2011).  
 
SPADI was used in this patient cohort due to its ability to evaluate shoulder function, specifically with 
regards to the functional movement at the level of the shoulder. SPADI is also short and easy for 
patients to complete (Paul et al. 2004).  
 
The resultant limitation in ADL may present a large challenge in LMICs such as South Africa, where 
oftentimes women are required to work in order to support the household. If a women is unable to 
work due to side effects from breast cancer treatment, this may have an impact on the family  in terms 
of poverty, lack of access to care and dependence on their partners for financial support (Mutebi & 
Edge 2014). The lack of structured rehabilitation and survivorship programmes means that access to 
upper limb rehabilitation often only occurs when patients present with advanced conditions of the 
shoulder.  
 
Long term surveillance and survivorship  
 
Given the burden of morbidity associated with breast cancer treatment, there is a clear need for  
prospective surveillance programmes that can be integrated into survivorship programmes, 
particularly within South Africa and other low-middle income countries. The ability to identify those 
patients at risk of long-term morbidity reduces the need for intensive rehabilitation and associated 
costs, which are not routinely part of the standard cancer care pathway (Shamley 2015).   
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Physiotherapy and exercise are able to resolve these problems (McNeely et al. 2010), however, there 
are insufficient resources to provide rehabilitation programmes for each cancer patient and therefore 
there is a need to identify and target resources, particularly in a country such as South Africa where 
resources are limited. Thus, there is a need for surveillance and early clinical identification (Hidding et 
al. 2014).  In order to design and implement integrated care pathways and service provision of upper 
limb deterioration, we require key baseline data to understand those patients who may be at risk and 
therefore better inform the development of those programmes.  
 
This study will aim to quantify the burden of shoulder morbidity in this selected population, and 




The primary objective of this study is to determine the prevalence of shoulder pain and disability of 
adult women attending their post-treatment annual follow up visit for unilateral breast carcinoma at 
a tertiary academic centre.  
 
The secondary objective is to evaluate associations between shoulder morbidity and covariates such 




This study will use data already collected from a primary study of women attending their annual breast 
clinic follow-up visit who completed the SPADI questionnaire, and thus is a secondary data analysis.  
 
9 | P a g e  
 
Ethical clearance for the primary study was granted by the University of Cape Town Human Research 
Ethics Committee (approval number: 312/2012).  
 
Women attending their annual check-up at the breast clinic at Groote Schuur Hospital, Cape Town, 
South Africa, were approached to be included in the study. Patients were reviewed according to pre-
determined inclusion and exclusion criteria (see section 4.1), and upon informed consent, participants 
completed the SPADI questionnaire in the language of their choice. Those requiring assistance to 
complete the questionnaire were assisted by research staff fluent in the language of the participant. 
No attempt was made to influence the participant’s score.  Additional clinical and demographic data 
was collected such as age, treatment protocol, tumour grade and side and location of primary tumour.  
 
This study will be a cross-sectional analysis of the prevalence of shoulder pain and dysfunction in this 
sample of women. This study will report on women attending a large, tertiary academic breast cancer 
clinic, and therefore may not be representative of the South African population in terms of racial 
groups, access and level of treatment relative to a primary or secondary care centre.  
 




1. Women 18 years of age and older  
2. One year post surgery for unilateral carcinoma of the breast 
 
Exclusion criteria:  
 
1. Reconstructive surgery 
10 | P a g e  
 
2. Current or previous history of shoulder complex trauma, surgery, pathology or dysfunction  
3. Current or previous history of cervical neuropathy  
 
 
3.2 Data Management and quality assurance  
 
Clinical and demographic data was collected from the participant’s hospital file and entered onto a   
case report form (CRF). Responses to the SPADI questionnaire were self-reported by the participants, 
in addition to information related to highest education level achieved and description of job duties. 
All information was captured independently into a RedCap database and is stored securely with 
access-control. The database has been 100% quality controlled twice.  
 
4. Statistical Considerations and Data Analysis 
 
4.1 Sample size 
 
This was a convenience sample of women attending annual follow up appointments at the breast 
clinic at Groote Schuur Hospital between 2015-2017. The SPADI questionnaire was completed by 
350 participants. Not all participants’ medical records provided the required demographic and 
clinical data.  
 
4.2 Statistical analysis 
 
The data will be exported from the database for analysis in STATA (College Station, Texas, USA). 
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Prevalence will be determined using summary statistics.  Regression analysis will be used for 
determining the association(s) between pain scores and covariates, such as baseline demographics, 
time since treatment, and treatment type.  Potential confounders and interacting variables will be 
considered in the analysis. A p-value of ≤ 0.05 will be considered statistically significant. 
5. Ethical Considerations 
5.1 Approval 
This study is using existing data from an approved primary study. Ethical clearance for the primary 
study was granted by the University of Cape Town Human Research Ethics Committee (approval 
number: 312/2012).   
 
5.2 Privacy and Confidentially 
 
Informed consent was received for all participants prior to collection of data. Personal information 
was de-identified and each participant was assigned a study number.  
 
5.3 Risk and Benefits to Participation  
 
The primary study presented minimal risks to the participants as no intervention was performed. 
Participation in the study did not benefit the participant. The results from this analysis will be 
disseminated and therefore will hopefully lead to an awareness of the need for post-cancer 
surveillance programmes.  
 
All participants who reported a mean pain and disability score above 6 were referred to a consultant 
for physiotherapy.  




The time required (and associated cost) for analysis and write-up will be self-funded by the masters 
student.   Funding will be provided for publication via an NRF grant held by Dr Delva Shamley (RRR 
Grant 93541).  
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1. Aim and Search Strategy 
 
The aim of this landscape literature review is to explore what is known about breast cancer treatment and 
resultant shoulder morbidities. The search strategy included a comprehensive search of several 
bibliographic databases (including Cochrane Library; Medline via PubMed, EBSCO, Scopus) and grey 
literature sources. All relevant studies available by July 2017 were included, regardless of publication 
status. Text words and Medical Subject Heading (MeSH) terms were used, and the literature search 
strategy was adapted to suit each database. A combination of the following terms were included:  Breast 
Neoplasms, Unilateral Breast Neoplasms, Breast cancer, Shoulder, Shoulder Pain, Shoulder morbidity, 
Shoulder pain, Shoulder weakness.  
 
2. Breast Cancer Incidence  
 
Breast cancer is the most frequently diagnosed cancer and leading cause of cancer death among women 
in both low-to-middle income countries (LMICs) and high-income countries (HICs) (Jemal et al. 2011). 
Approximately half the breast cancer cases and 60% of the deaths are estimated to occur in LMICs (Jemal 
et al. 2011).  Recent data from the United States (US) shows that breast cancer accounts for approximately 
one third of cancer diagnosed in women, with a lifetime risk of developing breast cancer of one in eight 
women (The American College of Obstetricians and Gynaecologists 2017). Data from the 2011 South 
African National Cancer Registry reports an incidence of breast cancer in women accounting for 21.46% of 
all cancers in females, with the greatest incidence occurring between the ages of 45-64 years (Herbst 2016; 
National Health Laboratory Service 2011). When broken down according to race, breast cancer accounts 
for similar proportions of total cancer in Black African and Caucasian women (20.87% for Black African and 
19.89% for Caucasian, respectively) with larger proportions in Asians (35.44%) and mixed ancestry women 
(26.63%) (National Health Laboratory Service 2011).    
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Internationally, there has been a considerable reduction in mortality due to breast cancer in the past 50 
years (The American College of Obstetricians and Gynaecologists 2017). It is estimated that of the 252,710 
new cases of breast cancer diagnosed in women in the US in 2017, 16% of these will result in death (The 
American College of Obstetricians and Gynaecologists 2017). Similarly within South Africa, mortality is 
estimated to be 15.9% according to data from 2012 (International Agency for Research on Cancer (IARC) 
n.d.). Coupled with that, the 5-year survival rate is substantially higher compared to the 1970’s 
(International Agency for Research on Cancer (IARC) n.d.).  Reduction in mortality is attributed to early 
detection with the use of screening programmes, and improvements in breast cancer treatment, including 
new therapies (The American College of Obstetricians and Gynaecologists 2017; UpToDate n.d.). However, 
international variation in incidence and survival rates still exist due to differences in reproductive and 
hormonal factors, and the availability of early detection services (UpToDate n.d.).  In LMICs such as South 
Africa, many patients present with advanced disease in addition to a lack of access to newest treatment 
options that may be available in HICs (Mutebi & Edge 2014; Marcus et al. 2013).  
 
3. Breast Cancer Treatment  
 
The medical management of breast cancer includes surgery, radiotherapy, chemotherapy, biological 
agents, endocrine (hormonal) therapy, and/or a combination of these (Tosello et al. 2014). There are 
several surgical treatment options including radical mastectomy (removal of the breast, lymph nodes and 
adjacent muscular tissue), modified radical mastectomy (MRM; removal of entire breast including axillary 
lymph nodes but not the muscular tissue) and breast conserving surgery (BCT) which is also known as 
lumpectomy or wide local excision (WLE) (Cotlar et al. 2003).  BCT was introduced in order to preserve the 
breast whilst achieving the same outcomes in terms of overall survival and disease-free survival as 
mastectomy, and several randomized controlled trials (RCTs) with long-term follow-up have demonstrated 
that BCT and mastectomy offer comparable survival (Poggi et al. 2003).  
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The use of axillary surgery (Axillary Lymph Node Dissection (ALND) or Sentinel Node Biopsy (SNB))  is 
associated with substantial morbidity and may lead to short- and long-term complications, including 
infection, wound healing problems, shoulder stiffness, pain and arm swelling (Peintinger et al. 2003).  Many 
patients receive surgery in combination with other treatments such as radiotherapy, chemotherapy, 
targeted therapy, and/or hormonal therapy.  
 
 
4. Breast Cancer Treatment Morbidity and Mortality 
 
Despite advances in survival due to improved treatment options, breast cancer surgery can result in short-
term and long-term complications, both physical and psychological (Borstad & Szucs 2012; Freitas-Silva et 
al. 2010; Cantarero-Villanueva et al. 2011). Psychological complications may include depression, difficulties 
at work and anxiety (Freitas-Silva et al. 2010).  From a physical perspective, BCT and mastectomy may result 
in impaired shoulder function including lymphoedema, pain, decreased range of motion (ROM), tightness, 
weakness, pain, numbness and Axillary Web Syndrome (AWS; also known as cording) (Freitas-Silva et al. 
2010; De Groef et al. 2016; Shamley 2015; Koehler et al. 2015). AWS presents as a visible palpable web of 
axillary skin which can feel like a rope and is associated with early ROM shoulder restrictions, tightness and 
pain during shoulder abduction (Koehler et al. 2015; Yeung et al. 2015). Patients experiencing shoulder and 
arm problems have significantly reduced functional use of their upper limb, which has a direct impact on 
their quality of life, ability to return to work, difficulty sleeping and functional activities, particularly 
overhead reaching (Shamley 2015; Borstad & Szucs 2012).  
 
There is large variability regarding the severity and onset of upper limb symptoms, occurring both in the 
short- and long-term period post-surgery  (Hidding et al. 2014; Gosselink et al. 2003). Reduced ROM, pain 
and lymphoedema are the most commonly described shoulder morbidities (Hidding et al. 2014). Shoulder 
mobility is less often impaired after SNB compared to ALND, with up to 87% of breast cancer survivors 
(BCS) having flexion and abduction ROM losses after ALND compared with 45% of those with SNB (Borstad 
5 | P a g e  
 
& Szucs 2012).  Even with the advent of less invasive surgery, a proportion of BCS will continue to 
experience upper limb limitations 2 or more years after treatment (Levangie & Drouin 2009), and may be 
present for up to six years post-surgery (Shamley et al. 2012; Shamley et al. 2009).  
 
Shoulder Morbidity  
 
Reduction in Range Of Motion (ROM) 
A systematic review of arm and shoulder morbidity in patients treated for breast cancer with ALND found 
reduction in ROM ranging from 1–67% (Hidding et al. 2014). Contrastingly, in patients treated with SNB, 
ROM occurred with a lower frequency of 6%–31% of patients after 12 months (Hidding et al. 2014).  A 
prospective study of 115 women post-surgery for breast cancer found that more than 60 % had ROM 
impairments in flexion and abduction and nearly 25 % experienced ROM loss in external rotation at month 
1 (Levy et al. 2012).   
 
Risk factors for reduced ROM include ALND, a greater number of lymph nodes removed, cording, seroma, 
mastectomy, stage II, hand dominance, BMI > 25 and older age (Hidding et al. 2014). Mastectomy was 
associated with a 5.67 times increased odds of reduced ROM when compared to lumpectomy (Hidding et 
al. 2014). Similarly, grade I level evidence shows an increased odds of reduced ROM with radiotherapy 
when compared to no radiotherapy (odds ratios ranging from 2.09 – 12.30) (Hidding et al. 2014; Levangie 
& Drouin 2009). The use of chemotherapy was associated with a 27% reduction in the odds of ROM 
reduction when compared with not receiving chemotherapy (Hidding et al. 2014).   
 
Reduction in muscle strength  
Reduced muscle strength has been reported in 17-28% of patients, with a greater proportion in those 
having received ALND (Hidding et al. 2014). Unlike reduced ROM with older age as a risk factor, muscle 
strength impairment has been associated with younger age (< 50 years) (Hidding et al. 2014). Similar to 
reduced ROM, chest radiotherapy was associated with an increased odds between 1.70 and 6.83 (Hidding 
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et al. 2014). Concurrent treatment with radiotherapy and chemotherapy (compared to sequential therapy) 
was also associated with a higher odds (Hidding et al. 2014).  
  
Pain 
Pain occurs between 9%–68%, with a greater incidence in those with ALND compared to SNB (Hidding et 
al. 2014).  When compared to no radiotherapy, chest radiotherapy pain has been reported in 26% vs. 4% 
of patients (OR = 7.10), up to 13 years post-surgery (Hidding et al. 2014). Likewise, hormonal therapy and 
radiotherapy have been shown to be the greater risk for pain (Hidding et al. 2014). Similar to reduced 
muscle strength, concurrent radiotherapy and chemotherapy (compared to sequential treatment) is 
associated with a greater incidence of pain (Hidding et al. 2014).  These findings may be similar as pain has 
been correlated with decreased muscle strength and ROM (Hidding et al. 2014). Contrasting to ROM 
reduction, chemotherapy has been associated with a 3 times greater odds of pain compared to no 
chemotherapy (Hidding et al. 2014).   In those patients with pre-existing pain prior to surgery, they are 5 
times more likely to experience post-operative and prolonged pain (Hidding et al. 2014).   
 
Lymphoedema  
Percentages of patients with lymphoedema ranges from 3%–13% for the first year post-surgery to 5%–35% 
in follow up (Hidding et al. 2014). ALND and high BMI are associated with an increased risk of 
lymphoedema, with a risk ratio of 3.47 for ALND and an odds ratio of 4.12 for BMI ≥30 (Freitas-Silva et al. 
2010; Hidding et al. 2014). Mastectomy, radiotherapy, and chemotherapy are also associated with a 
greater risk of developing lymphoedema (Hidding et al. 2014), in addition to a higher number of metastatic 
axillary lymph nodes (Freitas-Silva et al. 2010).   
 
Lymphoedema was compared in 44 women with BCT and 26 women with modified radical mastectomy 
and immediate breast reconstruction (MRM+IBR) by measuring the circumference of both arms (Freitas-
Silva et al. 2010). The prevalence of lymphoedema in the total population was 15.7%, with no 
significant difference between treatment modalities (12% for MRM+IBR and 18% for BCT, p=0.66) 
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(Freitas-Silva et al. 2010). However, in a study comparing MRM (n=186) or BCT (n=77) with radiotherapy 
±chemotherapy ± hormonal treatment (all had ALND), there was a significant difference between the 
prevalence of lymphoedema in the BCT group (8%) compared to the RM group (20%) (I. Nesvold et al. 
2009). Many studies report this inconsistency between surgery type and lymphoedema, and this may 
stem from the differing criteria used in addition to time elapsed between surgery and analysis (Freitas-
Silva et al. 2010). 
 
Reduction in Activities in Daily Living (ADL) 
ALND is associated with an increased risk of problems in performing daily activities when compared to SNB, 
according to level 2 evidence from a cohort study (Hidding et al. 2014). Similar to reduced ROM, older age 
is associated a greater risk of problems in performing daily activities when compared to younger people, 
with those between 65-74 years at highest risk (Hidding et al. 2014).  A cohort study found mastectomy 
with ALND to be associated with more problems conducting social activities compared to lumpectomy and 
ALND (Hidding et al. 2014). Radiotherapy, especially when the axilla was involved, has also been associated 
with a decrease in the degree of daily activities (Hidding et al. 2014).   
 
5. Predictors of Shoulder Morbidity   
 
Attempts to identify clinical risk factors have been hindered by the complexity of the condition and the 
many clinical variables involved in cancer management (Shamley & Robb 2015; Shamley 2015).  Several 
demographic and clinical characteristics contribute to the risk of developing shoulder pain and disability, 
such as age, tumour grade, and the type of treatment received. Moreover, risk profiles for early versus late 
shoulder effects differ. Early predictors of ROM impairment in a military population cohort included type 
of axillary surgery (ALND worse than SNB) , number of nodes removed and mastectomy, whereas older age 
and high body mass index (BMI) are associated with reduced ROM at 1 year (Levy et al. 2012).  
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A prospective study in the US evaluating demographic and clinical characteristics as predictors of change 
in shoulder ROM, grip strength, and functional interference found race, neoadjuvant chemotherapy, type 
of surgery and ALND as predictors of early onset, with living alone being an additional predictor over time 
(Smoot et al. 2016). This study evaluated upper extremity function 1 year after treatment, and thus these 
risk factors may or may not describe the predictors of long-term morbidity many years after treatment.   
Radiotherapy and chemotherapy have been linked to increased upper limb pain and dysfunction, 
suggesting a potential systemic cause of shoulder pain and dysfunction  (Shamley 2015; Hidding et al. 
2014). The acute effects of surgery, chemotherapy and radiotherapy all result in acute inflammation, skin 
changes and associated pain. Subsequent to the acute affects, shoulder morbidity remains a chronic 
condition, partly as a result of radiation-induced fibrosis (Straub et al. 2015).  
 
ALND vs. SNB 
Both ALND and SNB may result in shoulder impairments (Levangie & Drouin 2009), however, SNB is 
associated with a decreased prevalence of upper limb impairments and lymphoedema when compared to 
ALND  (De Groef et al. 2016).  Reduced ROM and muscle strength, pain, lymphoedema and decreased 
degree of activities in daily living are most frequently reported in relation to ALND (Hidding et al. 2014), 
with approximately 30% of patients developing shoulder-arm morbidity on the operated side after ALND 
(De Groef et al. 2016; Helms et al. 2009). Similar results were found in the Axillary Lymphatic Mapping 
against Nodal Axillary Clearance (ALMANAC) trial which compared SNB (n=424) to standard axillary 
treatment (n=405) (Mansel et al. 2006).  Post-operative arm morbidity and quality of life was assessed 
using the Functional Assessment of Cancer Therapy – Breast (FACT-B+4) instrument amended to include 
arm morbidity items, up to 18 months (Fleissig et al. 2006). At the end of the study, there was significantly 
more arm swelling and numbness in the standard group compared with the SNB group (14% versus 7% for 
swelling and 19% versus 8.7% for numbness), which in turn affected quality of life (Fleissig et al. 2006). 
Additionally, 28.3% of patients in the standard group reported at least 1 arm problem compared with 16.9% 
in the SNB group (p<0.001) (Fleissig et al. 2006). Older age and SNB had decreased effects on change in 
arm functioning scores from baseline to each of the study time points, although it is worth nothing that the 
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age groups were not balanced with respect to tumour grade, primary surgery and adjuvant treatment 
(Fleissig et al. 2006). There did not appear to be a difference in frequency of morbidity when comparing 
surgery on dominant side versus non-dominant side (Fleissig et al. 2006). Furthermore, the sequential use 
of SNB followed by ALND was compared to SNB alone in 181 women (Helms et al. 2009). In both objective 
and subjective measures, SNB scored better than the sequential treatment group (p < 0.001 for total 
scores) (Helms et al. 2009).  
 
Furthermore, another study comparing changes in shoulder strength 1 year after ALND or SNB found that 
strength decreased significantly at the first month after ALND, without having recovered pre-surgery values 
after 1 year of follow-up whereas no significant loss of strength was observed for patients treated with SNB 
at one month or 1 year (Monleon et al. 2016). It is worth noting that statistically significant differences in 
baseline characteristics existed between the SNB and ALND groups for BMI, type of surgery, tumour size, 
excised nodes and chemotherapy, which have also been associated with shoulder morbidity outcomes 
(Monleon et al. 2016). Similar to the data from De Groef et al and Helms et al, these data derive from 
studies with 1 year and 3 year follow up data, respectively, and therefore longer-term data would be useful 
to understand the long-term burden. Inherent in all of these observational studies is the potential for loss 
to follow up of those patients which may introduce a bias towards those seeking treatment for shoulder 
morbidity and pain management.  
 
A longitudinal study of 100 women 1 year after SNB found 49% had impaired shoulder function as 
measured by the Disability of Arm, Shoulder and Hand (DASH) questionnaire, with shoulder morbidities 
changing significantly over the 1 year period (De Groef et al. 2016). Importantly, patients with a higher BMI 
had a significantly greater decrease in shoulder function (De Groef et al. 2016).  
 
Radiotherapy 
Radiotherapy has been associated with impaired shoulder function and movement, with more extensive 
radiotherapy associated with long-term shoulder morbidity (Levangie & Drouin 2009). Notably, patients 
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receiving axillary radiotherapy (as opposed to chest wall radiotherapy alone) are at higher risk of late arm 
morbidity and greater disability of shoulder mobility and activities of daily living (ADL) (Levangie & Drouin 
2009; Gosselink et al. 2003). This may be due to diminished tissue healing or increased tissue fibrosis and 
stiffness affecting shoulder motion (Shamley et al. 2009; Gosselink et al. 2003). Various radiotherapy 
regimes were compared in the Standardisation of Breast Radiotherapy (START) trial, which randomised 
patients to different regimens and collected quality of life data for 2208 patients over the 5 years of follow-
up (Hopwood et al. 2010).  Arm and shoulder pain was reported in approximately a third of patients, with 
scores not differing between the regimens (Hopwood et al. 2010).  Of patients who received locoregional 
radiotherapy ± chemotherapy ± hormone therapy, 91% had some degree of arm/shoulder morbidity 
(Johansen et al. 2014). Dose level of radiotherapy was not associated with clinical endpoints, however, 
weak associations were shown between receiving approximately 15+ gray (Gy) and arm pain, arm stiffness, 
swollen arm, use of arm, numbness and shoulder abduction (Johansen et al. 2014).   
 
Race  
The impact of race was compared in a study in the US post-surgery for breast cancer. Participant who were 
Asian, Pacific Islander, Black or Hispanic (collectively compared as a group, ‘other’) were at a greater risk 
of developing adverse shoulder outcomes when compared to White women (Langford et al. 2014; 
Miaskowski et al. 2014; Smoot et al. 2016). The ‘other’ group reported worse shoulder morbidity, however, 
many of them also present with advanced disease requiring aggressive treatment, which may play a role 
in differences seen (Smoot et al. 2016).  
 
The impact of race on disability was compared among BCS using a validated scale called QuickDASH (Dean 
et al. 2015). Patients self-identified as Black (16%) or White (84%) (Dean et al. 2015). Black women had 7.3 
points higher average compared to White women (p<0.001) (Dean et al. 2015). After adjusting for key 
demographic and clinical factors (e.g. BMI, age, education, cancer treatment, months since diagnosis), 
Black women had 4 points higher average (p=0.04) (Dean et al. 2015). Interestingly, Black women 
presented with factors associated with greater upper extremity disability including increased BMI, older 
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age, more advanced disease at diagnosis, and underuse of SNB when compared with White women (Dean 
et al. 2015). It is important to note that mediation analysis suggested that BMI attenuated the association 
between race and disability by 40% thus reducing the strength of the association between race and 
disability (Dean et al. 2015).  
 
Race and arm pain was considered in another US study which evaluated demographic and clinical 
characteristics to assess differences in mild or moderate arm pain scores (Langford et al. 2014). Women 
who experienced moderate pain had significantly fewer years of education, lower Karnofsky Performance 
Status (KPS) scores, and higher comorbidity scores than those women with mild pain (Langford et al. 2014). 
Additionally, those in the moderate pain group had lower annual incomes, a higher number of 
postoperative complications, higher rates of depression (Langford et al. 2014). A greater proportion of 
black women experienced moderate pain whereas a greater proportion of white women experienced mild 
pain  (Langford et al. 2014; Miaskowski et al. 2014). A study of 287 women in Australia found older age, 
lower socioeconomic position, treatment on the dominant side, mastectomy, more extensive lymph node 
removal and having lymphoedema correlated with impairments in upper-body function (Hayes et al. 2010). 
Notably, none of these studies were of a South African Black population, and therefore inferences to our 
local population need to be taken with caution.  
 
In summary, consideration needs to be given to racial disparities with regards to cancer diagnosis and 
treatment. Differences relate to cancer stage at diagnosis, treatment options, survival, and quality of life 
outcomes (Blinder & Griggs 2013). Minorities, such as Black women, tend to be diagnosed with more 
advanced disease, are more likely to receive inferior treatment, and experience greater morbidity and 
mortality related to cancer and its treatment (Blinder & Griggs 2013).  
 
6. Measuring Shoulder Pain and Disability  
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Many tools have been developed to measure arm and/or shoulder pain and disability, including the 
Shoulder Pain and Disability Index (SPADI), Disabilities of the Arm, Shoulder and Hand (DASH), Oxford 
Shoulder Score (OSS), and Shoulder Rating Questionnaire (SRQ) (Roach et al. 1991; Breckenridge & 
McAuley 2011; Dawson et al. 2009; LeBlanc et al. 2014; Anon n.d.). Importantly, using shoulder-specific 
tools to measure function may help with rehabilitation (Borstad & Szucs 2012). The challenge of using 
objective measures rather than patient self-report is that they may fail to capture the extent that the 




Shoulder Pain and Disability Index (SPADI) 
 
SPADI is a self-administered index consisting of 13 items divided into two subscales; 5 for pain and 8 for 
disability (Roach et al. 1991). SPADI total and subscale scores are highly negatively correlated with shoulder 
ROM (Roach et al. 1991). Validation studies have shown internal consistency and reliability, and thus 
confirming its usefulness for both clinical and research purposes (Roach et al. 1991). The questionnaire is 
easy to complete and imposes very little burden on the patient (Torres-Lacomba et al. 2015). SPADI has 
been adapted cross-culturally into Spanish, and has shown excellent reliability and validity (test-retest 
reliability of 0.992 and Cronbach’s alpha of 0.965) (Torres-Lacomba et al. 2015).  
 
The SPADI index has been shown to identify key functional limitations in BCS associated with high, 
intermediate and low levels of pain and correlated with specific altered muscle activity and scapula 
deviation patterns, enabling it to be a surrogate marker for the early identification of patients at risk of 
developing advanced shoulder pain and dysfunction (Shamley & Robb 2015).  A study comparing a face 
version of the SPADI (using the Wong-Baker FACES scale) to the numerical SPADI scale in South African BCS 
confirmed excellent concurrent validity, internal consistency and test-retest reliability (manuscript 
submitted). 
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Oxford Shoulder Score (OSS) 
 
The Oxford Shoulder Score (OSS) is a valid and reliable patient-reported scale primarily developed for the 
assessment of outcomes of shoulder surgery in randomised trials, developed with the intention of 
minimising the influence of other co-morbidities (Dawson et al. 2009). OSS has been used in cohort studies, 
audits and registries (Dawson et al. 2009).  Similar to SPADI, it is easy to complete and has been translated 
into Spanish with good reliability and validity (test-retest reliability of 0.974 and Cronbach’s alpha of 0.947) 
(Torres-Lacomba et al. 2015).  
 
Disabilities of the Arm, Shoulder and Hand (DASH) 
 
Disabilities of the Arm, Shoulder and Hand (DASH) is a self-report 30-item questionnaire used to measure 
physical function and symptoms in any or all joints of the upper limb (Anon n.d.). It includes two optional, 
four-item modules in useful for athletes, performing artists and other workers whose jobs require a high 
degree of physical performance (Anon n.d.). It is one of the most commonly used patient reported 
outcomes (PRO) measures for upper extremity assessment, however, is not specific to shoulder only 
(LeBlanc et al. 2014). However, despite its common usage in breast cancer survivorship research, DASH 
psychometric properties have not been investigated in this population (LeBlanc et al. 2014).  
 
The QuickDASH is a shortened, convenient version of DASH comprising 11 items to measure physical 
function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb (Anon 
n.d.). DASH and QuickDASH are both valid, reliable and responsive and useful for daily clinical practice 
and/or research purposes (Anon n.d.; Hudak et al. 1996).  QuickDASH has also been shown to be valid and 
reliable in  assessing upper extremity disability in breast cancer patients (LeBlanc et al. 2014) 
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Shoulder Rating Questionnaire (SRQ) 
 
Shoulder Rating Questionnaire (SRQ) is a valid and reliable 21 question instrument used to examine 
subjective perception of shoulder function and has shown to be responsible in patients with many shoulder 
pathologies (Borstad & Szucs 2012). Several domains are measured on a 10 cm VAS or 5 point Likert scale, 
including global assessment, pain, daily activities, recreational and athletic activities, work, and satisfaction 
(Borstad & Szucs 2012).  
  
Kwan’s arm problem scale (KAPS) 
 
Kwan’s Arm Problem self-rating scale (KAPS) is used for the assessment of arm/shoulder problems and 
lymphoedema in patients treated for breast cancer with high reliability and validity (I. L. Nesvold et al. 
2009). There are 13 items in total; 8 items rating problems with arm/shoulder function, pain, stiffness and 
swelling, and 5 items rating impairment of ADL due to arm/shoulder problems (I. L. Nesvold et al. 2009). 
Items are rated on a 5 point Likert scale and are summed up to give a total score (I. L. Nesvold et al. 2009).   
 
Shoulder Disability Questionnaire (SDQ) 
 
The Shoulder Disability Questionnaire (SDQ) is a self-reported 16 item questionnaire evaluating functional 
status limitation in patients with soft tissue shoulder disorders (Van Der Heijden et al. 2000). It is quick and 
easy to complete, however, has primarily been used for patients in in a randomized placebo-controlled 
trial on ultrasound and electrotherapy as adjuvants to exercise therapy (Van Der Heijden et al. 2000).  
 
7. Gaps in Research and Moving Forward  
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There are no formal guidelines in South Africa for how to manage upper limb morbidities for BCS. 
Rehabilitation programmes are resource intensive and thus not implemented in standard cancer care 
pathways (Shamley & Robb 2015). Patients with shoulder problems often present to musculoskeletal 
practitioners who may not link the impairment to prior breast cancer treatment, particularly because these 
patterns of movement deviations resemble those seen in known shoulder conditions (Shamley et al. 2014; 
Shamley & Robb 2015). The challenge is that it is not feasible in many cancer centres to have a dedicated 
professional performing screening and treatment of all patients for motion impairments (Gritsenko et al. 
2015). 
 
The potential to identify predictors early on, particularly modifiable preoperative predictors, could have a 
significant impact on recovery of function after breast cancer treatment (Smoot et al. 2016; Hidding et al. 
2014; Shamley 2015). Knowledge of short term biomechanical changes at the shoulder will inform 
treatment decisions and may help prevent the development of shoulder pathology (Borstad & Szucs 2012). 
Additionally, a knowledge of risk factors provides important information for designing targeted 
rehabilitation programmes (Monleon et al. 2016).  Due to advances in treatment options and modalities, 
more women are surviving long term and therefore assessing upper extremity disability is an increasingly 
important issue, coupled with the fact that these disabilities persist into the long-term (Shamley et al. 2012; 
Hidding et al. 2014; Harrington et al. 2011).  
 
Therefore, long term, cost-effective surveillance programmes should be available to all patients and should 
identify those at risk of developing morbidity and target the interventions at the high risk population of 
patients (Shamley & Robb 2015). Physical therapy and exercise are effective interventions for improving 
function and overcoming arm morbidities such as ROM, strength, and oedema (Gritsenko et al. 2015; 
Shamley et al. 2005).  This would also have a significant impact on the public health burden of these 
patients, who are unable to return to work and require public health resources. A proposal of risk 
stratification may be employed to reduce cost and target those most at risk, including risk ascertainment a 
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few weeks post-surgery, several months post-surgery and long-term follow up, up to 10 years via a 
combination of questionnaires and online self-assessment (Shamley & Robb 2015). 
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Breast cancer is the most frequently diagnosed cancer and leading cause of 
cancer death among women, representing a considerable public health burden in 
South Africa and other low-middle income countries. Breast cancer 
management comprises of single or combination treatment including surgery, 
radiotherapy and chemotherapy. Short and long-term complications of these 
treatments include shoulder morbidities such as pain, decreased range of 
motion, tightness, weakness, pain, numbness and lymphoedema, and may be 
present for up to 6 years post-treatment. An understanding of baseline 
demographic and clinical risk factors can guide rehabilitation and management 
strategies for high risk patients.  
 
Materials and Methods 
 
This study was a cross-sectional analysis of the prevalence of shoulder pain and 
dysfunction in women attending their post-treatment annual follow up visit for 
unilateral breast carcinoma as measured by the Shoulder Pain and Disability 
Index (SPADI) questionnaire. The aim of this study was to quantify the burden 
of shoulder pain and disability in a tertiary academic hospital in Cape Town, 
                                                          
1 Co-authors: Dr DS Shamley and Mr J Ramjith  
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The majority of patients were of mixed ancestry, had their left side affected, 
received Axillary Lymph Node Biopsy and had undergone Modified Radical 
Mastectomy. The mean age was 60 years with a mean follow-up since surgery 
of 6 years. Three in four patients reported a presence of any pain or disability 
while only 9% experienced severe pain and disability.  Multivariable ordinal 
logistic regression analysis identified race, side, axillary surgery, chemotherapy 
and age as significant predictors of pain, and chemotherapy a significant 




The substantial burden of shoulder morbidity in this population represents a 
significant public health burden. The use of identified clinical and demographic 
characteristics may guide in the development of survivorship programmes 
incorporating surveillance and management of these high risk patients.  
 
Keywords: breast cancer, shoulder, morbidity, pain, disability, SPADI  
 
  




Breast cancer is the most frequently diagnosed cancer and leading cause of cancer death among 
women in both low-to-middle income countries (LMICs) and high-income countries (HICs) 
(Jemal et al. 2011). Approximately half the breast cancer cases and 60% of the deaths are 
estimated to occur in LMICs (Jemal et al. 2011). According to the 2011 South African National 
Cancer Registry, breast cancer accounts for 21% of all cancers in females, with the greatest 
incidence occurring between the ages of 45-64 years (Herbst 2016; National Health Laboratory 
Service 2011). This is accompanied by a mortality rate of 16% from 2012 (International 
Agency for Research on Cancer (IARC) n.d.), representing a considerable public health burden 
in South Africa (Herbst 2016).  In LMICs such as South Africa, many patients present with 
advanced disease and have a lack of access to newest treatment options that may be available 
in HICs (Mutebi & Edge 2014; Marcus et al. 2013). Screening programmes, early diagnosis 
and new treatments have an impact on reducing the mortality associated with breast cancer 
(UpToDate n.d.).   
 
The medical management of breast cancer includes surgery, radiotherapy, chemotherapy, 
biological agents, and hormonal therapy, as monotherapy or in combination (Tosello et al. 
2014). These treatment modalities may result in short and long-term complications, including 
impaired shoulder function such as pain, decreased range of motion (ROM), tightness, 
weakness, pain, numbness and lymphoedema (Freitas-Silva et al. 2010; De Groef et al. 2016; 
Shamley 2015; Koehler et al. 2015). These complications affect activities of daily living (ADL) 
including the ability to return to work (Shamley 2015). Reduced ROM, pain and lymphoedema 
are the most commonly described shoulder morbidities (Hidding et al. 2014) that occur shortly 
after surgery (Fleissig et al. 2006) and may be present for up to six years post-surgery (Shamley 
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et al. 2012; Shamley et al. 2009). The cause of shoulder pain and dysfunction is complex and 
multifactorial (Borstad & Szucs 2012) and attempts to identify clinical risk factors are 
challenged by the complexity of the condition and its resemblance to other shoulder conditions 
(Shamley & Robb 2015; Shamley 2015). Different treatment modalities are associated with 
varying levels of shoulder morbidity,  such as a higher prevalence in those receiving Axillary 
Lymph Node Biopsy (ALNB) compared to Sentinel Node Biopsy (SNB), in those receiving 
mastectomy compared to breast-conserving therapy (BCT), and with the use of chemotherapy 
and radiotherapy (De Groef et al. 2016; Shamley 2015; Levangie & Drouin 2009; Hidding et 
al. 2014; Smoot et al. 2016; Helms et al. 2009). Demographics associated with increased 
shoulder morbidity include the number of nodes removed, older age, the left side being affected 
and high body mass index (BMI) (Shamley et al. 2012; Shamley et al. 2009; Shamley et al. 
2007; Levy et al. 2012). Additionally, Black race, fewer years of education and lower annual 
income have been associated with higher levels of pain (Langford et al. 2014).   
 
The aim of this study was to quantify the burden of shoulder pain and disability in a tertiary 
academic hospital in Cape Town, South Africa, and identify potential risk factors for the 
development of shoulder morbidity.  
 
Materials and Methods 
 
Methods   
 
Women attending their annual check-up at the breast clinic at Groote Schuur Hospital, Cape 
Town, South Africa, were approached to be included in the study. Informed consent was 
received for all participants prior to collection of data. Personal information was de-identified 
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and each participant was assigned a study number. Patients were reviewed according to pre-
determined inclusion and exclusion criteria (see below), and upon informed consent, completed 
the Shoulder Pain and Disability Index (SPADI) questionnaire in the language of their choice. 
SPADI is a self-administered index consisting of 13 items divided into two subscales; 5 items 
for pain and 8 items for disability, which has shown consistency and reliability. The 
questionnaire is easy to complete and imposes very little burden on the patient. Those requiring 
assistance to complete the questionnaire were assisted by research staff fluent in the language 
of the participant. Additional clinical and demographic data was collected such as race (self-
identified), age, treatment protocol, tumour grade, side affected and number of involved nodes.  
 
This study is a cross-sectional analysis of the prevalence of shoulder pain and disability in this 
sample of women. The primary objective of this study was to determine the prevalence of 
shoulder morbidity within a tertiary academic centre, in patients attending their post-treatment 
annual follow up visit for unilateral breast carcinoma. The secondary objective was to evaluate 
associations between shoulder morbidity and covariates such as treatment protocol and baseline 
demographics. 
 
Inclusion and exclusion criteria 
Inclusion criteria: 
1. Women 18 years of age and older  
2. ≥1 year post surgery for unilateral carcinoma of the breast 
Exclusion criteria:  
1. Reconstructive surgery 
2. Current or previous history of shoulder complex trauma, surgery, pathology or 
dysfunction  
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3. Current or previous history of cervical neuropathy  
 
Statistical Considerations and Data Analysis 
Sample size 
This was a convenience sample of women attending annual follow up appointments at the 
breast clinic at the hospital between 2015 and 2017. The SPADI questionnaire was completed 
by 349 participants. Not all participants’ medical records provided the required demographic 
and clinical data.  
Statistical analysis: 
 
Data was analysed using STATA 14.0 (College Station, Texas, USA). Demographic and 
clinical data were described by summary statistics, where categorical variables (race and 
tumour grade) were reported in frequencies and percentages and numerical variables (age, 
time since surgery and nodes affected) were described by the mean and standard deviation.  
 
Pain and disability were categorised into four categories according to scores from the SPADI 
questionnaire where 0 depicts ‘no pain/no disability’, 1-30 ‘mild pain/mild disability’, 31-50 
‘moderate pain/moderate disability’ and >50 ‘severe pain/severe disability’, respectively. 
Ordinal logistic regression was used for determining the association(s) between pain and 
disability scores with covariates, such as baseline demographics and treatment type.  Ordinal 
logistic regression was used due to the presence of several ordered categories of the outcomes, 
pain and disability. Potential confounders and interacting variables were considered in the 
analysis. In the univariable analysis, odds ratios (OR) and 95% confidence intervals (CIs) were 
calculated to summarize the effect of each covariate on pain and disability outcomes. 
Covariates with a p-value <0.2 in the univariate analysis were selected for consideration in the 
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multivariable model. A backward selection procedure was used to investigate the most 
significant predictors of pain and disability scores in the multivariable analysis. The final model 
was presented by the OR and 95% CI for the OR of the predictor. A p value of <0.05 was 
considered statistically significant. The proportional odds assumption was investigated for the 






Ethical clearance for this study was granted by the University of Cape Town Human 
Research Ethics Committee (approval number: 317/2017). This study was conducted in 
accordance with the Declaration of Helsinki (last updated in 2013) and International 




Demographic and clinical characteristics are summarised in Table 1. The majority of patients 
were of mixed ancestry (77%) with the remainder Black African (14%) and Caucasian (7%). 
Age ranged from 34 – 84 years, with a mean (standard deviation [SD]) of 60 (10.32) years. 
Follow-up was on average 6 and a half years (SD 2.43) since surgery, with a minimum of 2 
years and maximum of 17 years.  Slightly more participants had left affected side compared 
to right (51% vs. 44%; p >0.05). More patients had tumour grade II (43%) compared to 
tumour grades I (18%) and III (19%), and the majority of patients had also received 
additional treatments such as chemotherapy (72%), hormonal therapy (70%) and radiotherapy 
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(63%), respectively.   The large majority of patients underwent ALND compared to SNB 
(78% vs. 13%). There were no radical mastectomies, but 70% modified radical mastectomy 
(MRM) and 18% wide local excision (WLE).  Many patients received a combination of 





Table 1. Participant Demographic and Clinical Characteristics 
Variable  Number of Participants  % or Mean (SD) 
Race (N = 349)    
Black African    50 14.33 
Caucasian  24 6.88 
Mixed ancestry  269 77.08 








Affected side (N = 349)  
  
Left 179 51.29 
Right 155 44.41 
Missing  15 4.30 
 
Tumour grade (N = 349)  
  
1 66 18.91 
2 153 43.84 
3 68 19.48 
Missing  62 17.77 
 












Surgery type (N = 349) 
  
MRM 256 73.35 
WLE 64 18.34 
Missing  29 8.31 
 
Axillary Surgery  (N = 349)  
  
SNB 46 13.18 
ALND  273 78.23 
Missing  30 8.60 
 
Chemotherapy (N = 349) 
  
10 | P a g e  
 
Yes  254 72.78 
No  37 10.60 
Missing  58 16.62 
 
Hormonal therapy (N = 349) 
  
Yes  246 70.49 
No  43 12.32 
Missing  60 17.19 
 
Radiotherapy (N = 349) 
  
Yes  221 63.32 
No  120 34.48 
Missing  8 2.29 
 





WLE + radiotherapy 60 95.24 
MRM + chemotherapy  199 88.44 
WLE + chemotherapy  41 78.85 
SD = Standard Deviation  
MRM = Modified Radical Mastectomy 
WLE = Wide Local Excision  
 
 
A summary of the SPADI results are presented in Table 2, according to individual items and 
total scores for pain and disability, respectively. Overall, the prevalence of shoulder 
morbidity in this population was 75% with only a quarter of patients reporting no pain or 
disability (a score of 0).  When considered according to severity grading, half the patients had 
mild total SPADI scores, a quarter reported no pain or disability, and moderate and severe 
collectively accounted for the remaining quarter. There was a significant difference between 
total SPADI score when comparing the proportion who reported mild versus the proportion 
who reported moderate (p < 0.001) whereas there was no significant difference between the 
proportion who reported moderate versus the proportion who reported severe SPADI scores 
(p = 0.13).   
 
When evaluating the congruence between pain and disability, 26% had no pain and 38% had 
no disability, whereas 14% had severe pain and 7% severe disability. Overall, more pain is 
present relative to disability. Similarly, as seen in Figure 1, there is not a complete association 
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between all categories of pain and disability. In those with severe disability, a large 
proportion also had severe pain. However, in those with mild disability, although the large 
majority also had mild pain – many also reported both moderate and severe pain. Similarly, 
moderate disability comprised of both moderate and severe pain. The Pearson’s correlation 
coefficient between pain and disability scores was 0.82 showing a strong linear relationship 
between pain and disability.  
 
As seen in the individual components of pain and disability in Table 2, 74% of patients 
experienced some degree of pain (similar to the overall shoulder morbidity of 75%) whereas 
63% experienced some level of disability. Mild pain was experienced by 46% of patients, and 
moderate and severe pain by 14% of patients, respectively.  Mild disability was experienced 
by 53% of patients, moderate by 13%, and severe disability by 9% of patients.  
 











At its worst 86 (27) 75 (24) 51 (16) 103 (33) 
Lying on involved side 169 (53) 60 (19) 42 (13) 50 (15) 
Reaching on a high shelf 165 (51) 85 (27) 28 (9) 43 (13) 
Touching the back of your 
neck 
86 (53) 31 (19) 17 (11) 27 (17) 
Pushing with the involved 
arm 
210 (66) 44 (14) 27 (8) 38 (12) 










Washing your hair 268 (83) 21 (7) 14 (4) 18 (6) 
Washing your back 216 (68) 27 (8) 25 (8) 51 (16) 
Putting on an undershirt 
or pulling on a sweater 
264 (83) 19 (6) 10 (3) 27 (8) 
Putting on a shirt on with 
buttons down the front 
300 (93) 11 (3) 4 (1) 6 (2) 
Putting on your pants 284 (88) 16 (5) 7 (2) 14 (4) 
12 | P a g e  
 
Placing an object on a 
high shelf 
202 (63) 48 (15) 27 (8) 43 (13) 
Carrying a heavy object 
of 4.5kg 
152 (47) 57 (18) 34 (11) 78 (24) 
Removing something 
from your back pocket 
268 (84) 24 (8) 9 (3) 17 (5) 
Disability Total 122 (38) 146 (46) 31 (10) 21 (7) 






Ranking scale for severity grading: 
 
For Total Pain, Disability, and SPADI:  For Pain and Disability individual questions: 
 
None: score of zero    None: score of zero  
Mild: score of 1-30     Mild: score of 1-3 
Moderate: score of 31-50    Moderate: score of 3 -5 
Severe: score >50     Severe: score > 5 
 
Figure 1: Stacked Bar Chart showing the association between Categories of SPADI Pain 
and Disability  
 
 
Table 3 and Table 4 summarize the results from univariable and multivariable ordinal logistic 
regression with respect to pain (Table 3) and disability (Table 4). Pain and disability, were 











None Mild Moderate Severe
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ranked on an ordinal scale as none, mild, moderate and severe. The odds ratio is interpreted as 
the increase in odds of being in a higher pain or disability category per unit increase in the risk 
factor. The proportional odds assumptions was met for the final models of both pain and 
disability.  
 
Utilizing univariable ordinal logistic regression analysis, variables associated with pain in this 
population group (all p <0.2)  were: race, the affected side of the primary tumour, total 
number of nodes affected, use of chemotherapy as an additional treatment modality, age, use 
of radiotherapy as an additional treatment modality, and axillary surgery (Table 3).  In the 
multivariable ordinal logistic regression analysis, race, side, axillary surgery, chemotherapy 
and age remained as the most significant predictors of pain, whereas radiotherapy was no 
longer significant.   
 
As seen in Table 3, Caucasian and mixed ancestry patients experienced less pain compared to 
Black African  patients, but this OR was not statistically significant for mixed ancestry 
patients (Caucasian: OR 0.21; 95% CI 0.05 – 0.82, p = 0.024 and mixed ancestry: OR 0.54; 
95% CI 0.22 – 1.37, p = 0.194). Those patients who had the left side affected had 3.2 times 
increased odds of being in worse pain (OR 3.22; 95% CI 0.97 - 10, p = 0.056) compared with 
patients who had their right side affected.  For each unit increase in age there was a 
corresponding 5% reduction in the odds of being in a higher pain category (OR 0.95; 95% CI 
0.93 – 0.98, p < 0.0001). The lack of chemotherapy as an additional treatment was associated 
with a 61% reduction in the odds of pain (OR 0.39; 95% CI 0.18-0.83, p =0.015). ALND was 
associated with a reduced odds of being in a higher pain category by 52% (OR 0.48; 95% CI 
0.23-0.98, p = 0.044)  
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To directly test the hypothesis that the side effect may differ by race, an overall model was 
constructed that included the covariates described, and an interaction term for race and side. 
Both the covariates remained significantly associated with higher pain, as did the interaction 
term for Caucasian when compared to the reference group of Black African  (p = 0.034), but 
not for mixed ancestry when compared to the reference group of Black African  (p = 0.156). 
Exploratory analysis of additional interaction terms showed no significant association with 
the outcome. 
 
Covariates found to be correlated with disability in univariable ordinal logistic regression 
analysis included race, chemotherapy, age, radiotherapy and axillary surgery (Table 4).  In 
the multivariable logistic regression analysis, chemotherapy was the only one that remained 
as a significant predictors of disability, after adjustment. The lack of exposure to 
chemotherapy as an additional treatment modality was associated with a 63% reduction in the 
odds of experiencing a worse category of disability (OR 0.37, 95% CI 0.18 – 0.77, p = 
0.007).  
 
Table 3: Ordinal Logistic Regression for Pain Categories  
 
Univariable Multivariable 
OR (95% CI) OR (95% CI) 
Race   
Black African  
(Reference) 
  
Caucasian 0.46 (0.18, 1.18) 0.21 (0.05 – 0.82)* 
Mixed ancestry   0.49 (0.28, 0.88) 0.54 (0.22 – 1.37) 
 
Right Side  
 
0.77 (0.51, 1.17) 
 




1 (Reference)   
2  1.27 (0.73, 2.20)  
3  1.30 (0.68, 2.48)  
 
Total nodes  
 
0.98 (0.94, 1.01) 
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No Chemotherapy 0.35 (0.17, 0.72) 0.39 (0.18, 0.83)* 
 
No Hormonal Therapy 
 
0.97 (0.53, 1.77) 
 
 
Date of Surgery 
 










0.95 (0.92, 0.98) 
 
0.95 (0.93 – 0.98)** 
 
Surgery Type  
  
MRM (Reference)   
WLE 1.10 (0.65, 1.88)  
 
Axillary Surgery  
  
SNB (Reference)   
ALND 0.64 (0.35, 1.16) 0.48 (0.23, 0.98)* 
 
Interaction of Race and 
Side 
  
Caucasian 0.14 (0.04, 0.49)  
Mixed ancestry   0.26 (0.11, 0.58)  
Right side  0.24 (0.08, 0.72)  
Caucasian/right 13.81 (1.96, 97.47) 8.92 (1.17 – 76.76)* 
Mixed ancestry/right 3.57 (1.07, 11.88) 2.55 (0.70 – 9.33) 
   
MRM = Modified Radical Mastectomy   
* p<0.05, ** p<0.01 
 
 




OR (95% CI) OR (95% CI) 
Race   
Black African  
(Reference) 
  
Caucasian 0.35 (0.14, 0.88)  
Mixed ancestry   0.55 (0.31, 0.97)  
 
Right Side  
 





1 (Reference)   
2  1.13 (0.64, 1.98)  
3  1.33 (0.69, 2.58)  
 
Total nodes  
 





0.37 (0.18, 0.77) 
 
0.37 (0.18 – 0.77)** 
 
No Hormonal Therapy 
 
1.21 (0.65, 2.23) 
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0.97 (0.95, 1.00) 
 
 
Surgery Type  
  
MRM (Reference)   
WLE 0.82 (0.48, 1.42)  
 
Axillary Surgery  
  
SNB    
ALND  0.99 (0.54, 1.81)  
   




This analysis reports on a group of individuals in a LMIC state-provided facility in Cape 
Town, South Africa. Approximately 600 new patients and many more follow-ups are seen 
annually at this large, tertiary academic breast cancer clinic, from a broad range of referral 
centres within Cape Town.  On average, patients were 6.52 years post-surgery when they 
were enrolled into this study, with a minimum of 2.37 years and a maximum of 17.5 years, 
representing long-term outcome data post-surgery for breast cancer. This is a similar finding 
to previous work from an author in this group from a European population group showing 
that pain continues to persistent 6 years after treatment (Shamley et al. 2012).  This similarity 
exists in the presence of a large number of radical mastectomies in this patient group 
compared to those in the European study (Shamley et al. 2012).  
 
A total of 75% of patients experienced some level of pain and disability, with 25% 
experiencing none at all. The overall percentage was almost identical for both total SPADI 
score and the domain of pain scores (75% and 74%, respectively), whereas the disability 
score was somewhat less with 63% experiencing mild, moderate or severe disability. These 
figures represent a significant burden of long-term morbidity. The reduced prevalence of 
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disability compared to pain indicates that pain may be the more significant burden of 
shoulder morbidity, accompanied by disability in the large majority. According to overall 
SPADI score, 53% of patients were mild, 13% moderate, and 9% severe, respectively. The 
proportion of patients in each group of overall SPADI score was statistically significantly 
different when comparing mild versus moderate groups, but not for moderate versus severe 
groups, respectively.  Mild pain and disability accounts for the largest group; 46% of patients 
in each of the domains. Differences lie between pain and disability in the moderate and 
severe groups, suggesting that more pain exists but not necessarily in the presence of 
accompanying disability.  
 
Separate ordinal logistic regression models were constructed for pain and disability due to the 
differing burden each one represents, as seen from Table 2 and Figure 1. The proportional 
odds assumptions were met for the final multivariable ordinal regression models of pain and 
disability, confirming the ORs increase at a consistent proportion in the model. Whereas age, 
side affected, chemotherapy, axillary surgery and race were risk factors for pain, only the use 
of chemotherapy was a risk factor for disability.  
 
Black African patients had a greater odds of being in the higher pain categories, when 
compared to Caucasian and mixed ancestry patients.  We are aware of differences existing 
between racial groups indicating that Black patients are at a higher risk, although this is 
largely from the African-American population (Dean et al. 2015; Blinder & Griggs 2013). 
Differences between the racial groups may exist due to cultural approaches to treatment-
seeking behaviours, delays in seeking or accessing treatment and socioeconomic status 
(SES). The prevalence of obesity is often higher in the Black population, particularly Black 
women (Hendley et al. 2011) and given high BMI is a known risk factor for shoulder 
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morbidity (Hidding et al. 2014), one needs to consider the presence of obesity in Black 
patients as a mediator of pain (Dean et al. 2015). Mediation analysis has suggested that BMI 
can attenuate the association between race and disability by 40% (Dean et al. 2015).  
However, as this was not measured in our study, we cannot make inferences regarding it. 
This is a public sector hospital and therefore patients seen are generally at a lower SES, 
which in addition to being of Black African  race, may be associated with presenting with 
more advanced disease and receiving fewer treatment options (Dean et al. 2015; Smoot et al. 
2016; Blinder & Griggs 2013). 40% of patients presented with grade II tumours, although 
18% had missing data for this variable.  A recent study at this breast cancer facility found that 
78% of women were unemployed despite having received treatment more than 2 years prior 
(personal communication).  It is important to note that more than 70% of the patients 
included in the group were of mixed ancestry. This is not reflective of the South African 
population where the largest racial group is Black African , however, it is representative of 
the Cape Town region where mixed ancestry is the largest population group (Anon 2014).  
 
In this study, the mean age was 60 years, ranging from 34 to 83 years. Increasing age was 
statistically significantly associated with reduced pain, with an OR of 0.95 (95% CI 0.93 – 
0.98, p < 0.0001). Older age is a risk factor for reduced ROM and limitation in ADL, 
however, younger age is associated with reduced muscle strength (Hidding et al. 2014). This 
discrepancy may be due to younger patients being more sensitive to the discomfort resulting 
from axillary surgery or having different expectations (Fleissig et al. 2006). A study with a 
relatively similar population age group to ours (mean age of patients were 56 years) found 
age to be a strong predictor of long-term shoulder–arm function (Kootstra et al. 2013). Liu et 
al. (Liu et al. 2009) concluded that younger age was a strong predictor of late morbidity, 
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which correlates with our finding that the younger you are, the worse your pain, particularly 
in our group of long-term follow up patients.  
 
When considering side affected, there was a relatively even split of left and right side 
affected, with slightly more left affected.  Left side affected was associated with a higher risk 
of pain, which corroborates what has been shown previously. It is well understood that left 
affected side represents a higher risk group for development of pain and disability (Shamley 
et al. 2009). A number of other studies have also reported increased frequency of pain on the 
left side (Shamley et al. 2012; Shamley et al. 2007).   
 
Chemotherapy treatment was associated with a 37% increased odds of having a worse 
disability score and 39% of having a worse pain score. Chemotherapy has been linked to 
increased upper limb pain and dysfunction and lymphoedema (Shamley 2015; Gosselink et 
al. 2003; Hidding et al. 2014), although has also been shown to reduce the odds of reduced 
ROM reduction when compared with not receiving chemotherapy (Hidding et al. 2014). 
Further analysis was not able to be conducted related to the specific type of chemotherapy 
received, how many cycles were received and whether it was as adjuvant or neoadjuvant 
therapy, respectively. ALND was associated with reduced pain when compared to SNB. This 
is a surprising finding given most of the evidence suggests that SNB has more favourable 
outcome in terms of shoulder morbidity (De Groef et al. 2016; Hidding et al. 2014). A similar 
proportion of patients in both groups received hormonal treatment, radiotherapy and 
chemotherapy. Furthermore, more patients in the ALND groups also had left side affected 
(57% ALND vs. 33% SNB). Many patients had received additional treatments with 
chemotherapy (70%), radiotherapy (63%), and hormonal treatment (70%). Given 
radiotherapy result in long-term morbidities, including diminished tissue healing or increased 
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tissue fibrosis, perhaps this provides evidence of shoulder morbidity being less related to type 
of axillary surgery only, but rather the additional other treatments (Gosselink et al. 2003). 
 
The SPADI questionnaire was used as it is quick and easy to complete (Torres-Lacomba et al. 
2015). It has also been shown to have high reliability and validity (Roach et al. 1991) and is 
able to identify key functional limitations in breast cancer survivors, making it a useful tool 
for identification of patients at risk of developing shoulder pain and disability (Shamley 
2015). It has not be validated in a South African population, however, a study evaluated the 
concurrent validity, construct validity and the test-retest reliability of a Face-SPADI in South 
African breast cancer survivors, and showed excellent concurrent validity, internal 
consistency and test-retest reliability (personal communication). Thus we can be confident of 
the results of this study which utilised the SPADI numerical questionnaire.  
 
There are several limitations to this study. There is a proportion of missing demographic and 
clinical data, particularly with respect to tumour grade, surgical techniques employed and the 
use of chemotherapy and hormonal treatment. This may affect some of the statistical analysis 
with regards to regression in terms of sample size and confidence intervals. Although 10 
patients did not fully complete the SPADI questionnaire, the questionnaire makes adjustment 
for this in the calculation.   Although internal validity is likely to be high, there is limited 
external generalizability. However, this study was aimed at providing data for a specific 
groups of patients in a LMIC.  No patients in this group underwent a radical mastectomy, as 
this is not the clinical treatment pathway of this hospital. We are aware that radical 
mastectomy is a risk factor for shoulder morbidity so perhaps this may underrepresent the 
burden. The SPADI questionnaire requires self-reporting of pain and disability, introducing 
the challenges of subjective reporting and self-perceived outcomes. However, as discussed 
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above, SPADI has been shown to be reliable and valid, and has frequently been employed in 
research settings for assessment of shoulder dysfunction.  
 
The fact that this data shows such a significant burden of shoulder morbidity 6 years after 
treatment highlights the importance of long-term surveillance and rehabilitation. There is a 
clear need for prospective surveillance programmes that can be integrated into survivorship 
programmes, particularly within South Africa and other LMICs (Shamley & Robb 2015; 
Hidding et al. 2014). The ability to identify those patients at risk of long-term morbidity 
reduces the need for intensive rehabilitation and those associated costs (Shamley & Robb 
2015). Physiotherapy and exercise are able offer support for these problems (McNeely et al. 
2010), however, there are insufficient resources to provide these for each cancer patient 
routinely and therefore there is a need to identify and target resources, particularly in a 
country such as South Africa where resources are limited. This has an economic public health 
burden in that many of these women require to contribute to their households in order to feed 
and house their families. Oftentimes, these women work in jobs that require a high level of 
physical functioning, and thus the inability to move one’s shoulder represents a significant 
barrier to return to work. Rehabilitation would reduce the public health burden in an already-
burdened service and public health sector facility.  Having key baseline data and predictors 
enables us to design and implement care pathways for those patients at risk. A greater focus 
needs to be given to survivorship strategies, surveillance and early intervention warning 
systems as part of an integrated cancer care model.  
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Appendix 1: SPADI Questionnaire  
 
Pain Scale 
How severe is your pain? 
Circle the number that best describes your pain where: 0 = no pain at all and 10 = the worst pain 
imaginable 
1.At its worst? 0 1 2 3 4 5 6 7 8 9 10 
2.When lying on the involved side? 0 1 2 3 4 5 6 7 8 9 10 
3.Reaching for something on a high shelf? 0 1 2 3 4 5 6 7 8 9 10 
4.Touching the back of your neck? 0 1 2 3 4 5 6 7 8 9 10 
5.Pushing with the involved arm? 0 1 2 3 4 5 6 7 8 9 10 
 
Disability Scale 
How much difficulty do you have? 
Circle the number that best describes your experience where: 0 = no difficulty and 10 = so difficult it 
requires help 
1.Washing your hair? 0 1 2 3 4 5 6 7 8 9 10 
2.Washing your back? 0 1 2 3 4 5 6 7 8 9 10 
3.Putting on an undershirt or jumper? 0 1 2 3 4 5 6 7 8 9 10 
4.Putting on a shirt that buttons down the 
front? 
0 1 2 3 4 5 6 7 8 9 10 
5.Putting on your pants? 0 1 2 3 4 5 6 7 8 9 10 
6.Placing an object on a high shelf? 0 1 2 3 4 5 6 7 8 9 10 
7.Carrying a heavy object of 10 pounds (4.5 
kilograms) 
0 1 2 3 4 5 6 7 8 9 10 
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8.Removing something from your back 
pocket? 
0 1 2 3 4 5 6 7 8 9 10 
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Appendix 3: Acta Oncologica Journal Instructions for Authors   
 (http://www.tandfonline.com/action/authorSubmission?journalCode=ionc20&page=instructions)  
About the journal 
Acta Oncologica is an international, peer reviewed journal, publishing high-quality, original 
research. Please see the journal’s Aims & Scope for information about its focus and peer-
review policy. 
Please note that this journal only publishes manuscripts in English. 
This journal accepts the following article types: original articles, reviews, letters, 
correspondence, technical notes and short communications. 
Peer review 
Taylor & Francis is committed to peer-review integrity and upholding the highest standards 
of review. Once your paper has been assessed for suitability by the editor, it will then be 
single blind peer-reviewed by independent, anonymous expert referees. Find out more 
about what to expect during peer review and read our guidance on publishing ethics. 
Preparing your paper 
All authors submitting to medicine, biomedicine, health sciences, allied and public health 
journals should conform to the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, prepared by the International Committee of Medical Journal Editors 
(ICMJE). 
Structure 
The text should, usually, be divided into the sections: Introduction, Material and Methods, 
Results, and Discussion. 
Word limits 
Please include a word count for your paper.  
There are no word limits for articles in this journal. 
Style guidelines 
Please refer to these style guidelines when preparing your paper, rather than any published 
articles or a sample copy. 
Please use British or American spelling style consistently throughout your manuscript. 
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Please use single quotation marks, except where 'a quotation is "within" a quotation'. Please 
note that long quotations should be indented without quotation marks. 
Abbreviations, which are not generally accepted, should be spelled out when first used in 
text. Uncommon abbreviations and clinical jargon should be avoided. 
Footnotes are not accepted. 
Formatting and templates 
Papers may be submitted in any standard format, including Word. Figures should be saved 
separately from the text. To assist you in preparing your paper, we provide formatting 
templates. 
Word templates are available for this journal. Please save the template to your hard drive, 
ready for use. 
If you are not able to use the templates via the links (or if you have any other template 
queries) please contact authortemplate@tandf.co.uk 
Please supply your manuscript typed with double spacing throughout the article (at least 1 
cm between the lines) and margins of at least 4 cm on the left side and at the top. 
1. Please be consistent. The same elements should be keyed in exactly the same way throughout the 
manuscript. 
2. Do not break words at the end of lines. Use a hyphen only to hyphenate compound words. 
3. Enter only one space after the full-stop at the end of a sentence. 
4. When emphasizing words please use the italic feature of your word processor software. 
5. Do not justify your text; use a ragged right-hand margin. 
6. Use a double hyphen (--) to indicate a dash in text. 
7. Do not use the lowercase l for 1 (one) or the uppercase O for 0 (zero). 
8. The space bar should only be used as a word separator. Use TAB when identifying paragraphs or 
separating columns in tables. 
Tables  
Type each table double-spaced on a separate page. Do not submit tables as photographs. 
Supply a brief title for each table. Give each column a short or abbreviated heading. Place 
explanatory matter in notes under the table, not in the heading. 
Please Note: Journal instructions require tables to be double spaced, however, tables have 
been presented in dissertation with single spacing for ease of readability 
Illustrations  
Submit illustrations as separate files in TIFF or EPS format, and stored with an image 
resolution of at least 300 DPI (line figures preferably higher). Figure number should be 
indicated in the file name. Figure legends should be provided at the last page of the main 
text. Letters and numerals should be large enough to allow reduction of illustrations to one-
column width (8 cm). Please indicate in Manuscript Central which of the figure images that 
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you wish to print in colour in the journal, and acknowledge the printing costs for colour 
figures. The current rate is $200 per article. This cost must be bourne by the author(s). 
References 
Please use this reference style guide when preparing your paper. An EndNote output style is 
also available to assist you. 
Checklist: what to include 
1. Author details. Please ensure everyone meeting the International Committee of Medical Journal 
Editors (ICMJE) requirements for authorship is included as an author of your paper.Please ensure 
everyone meeting the International Committee of Medical Journal Editors (ICJME) requirements for 
authorship is included as an author of your paper.Please include all authors’ full names, affiliations, 
postal addresses, telephone numbers and email addresses on the title page. Where available, please 
also include ORCID identifiers and social media handles (Facebook, Twitter or LinkedIn). One author 
will need to be identified as the corresponding author, with their email address normally displayed 
in the article PDF (depending on the journal) and the online article. Authors’ affiliations are the 
affiliations where the research was conducted. If any of the named co-authors moves affiliation 
during the peer-review process, the new affiliation can be given as a footnote. Please note that no 
changes to affiliation can be made after your paper is accepted. Read more on authorship. 
2. A structured abstract of no more than 300 words. Abstracts should be structured and arranged 
according to the same headings that are used in the text; Background, Material and Methods, 
Results and Conclusion. An abstract is required for all manuscript types, except for 'Letters to the 
Editor' and other Read tips on writing your abstract. 
3. Graphical abstract(Optional) . This is an image to give readers a clear idea of the content of your 
article. It should be a maximum width of 525 pixels. If your image is narrower than 525 pixels, please 
place it on a white background 525 pixels wide to ensure the dimensions are maintained. Save the 
graphical abstract as a .jpg, .png, or .gif. Please do not embed it in the manuscript file but save it as a 
separate file, labelled GraphicalAbstract1. 
4. You can opt to include a video abstract with your article. Find out how these can help your work 
reach a wider audience, and what to think about when filming. 
5. 4-7 keywords. Read making your article more discoverable, including information on choosing a title 
and search engine optimization. 
6. Funding details. Please supply all details required by your funding and grant-awarding bodies as 
follows:  
For single agency grants: This work was supported by the[Funding Agency] under Grant [number 
xxxx].  
For multiple agency grants: This work was supported by the [funding Agency 1]; under Grant 
[number xxxx]; [Funding Agency 2] under Grant [number xxxx]; and [Funding Agency 3] under Grant 
[number xxxx]. 
7. Disclosure statement. This is to acknowledge any financial interest or benefit that has arisen from 
the direct applications of your research. Further guidance on what is a conflict of interest and how to 
disclose it. 
8. Supplemental online material. Supplemental material can be a video, dataset, fileset, sound file or 
anything which supports (and is pertinent to) your paper. We publish supplemental material online 
via Figshare. Find out more about supplemental material and how to submit it with your article. 
9. Figures. Figures should be high quality (1200 dpi for line art, 600 dpi for grayscale and 300 dpi for 
color, at the correct size). Figures should be saved as TIFF, PostScript or EPS files. More information 
on how to prepare artwork. 
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10. Tables. Tables should present new information rather than duplicating what is in the text. Readers 
should be able to interpret the table without reference to the text. Please supply editable files. 
11. Equations. If you are submitting your manuscript as a Word document, please ensure that equations 
are editable. More information about mathematical symbols and equations. 
12. Units. Please use SI units (non-italicized). 
Using third-party material in your paper 
You must obtain the necessary permission to reuse third-party material in your article. The 
use of short extracts of text and some other types of material is usually permitted, on a 
limited basis, for the purposes of criticism and review without securing formal permission. If 
you wish to include any material in your paper for which you do not hold copyright, and 
which is not covered by this informal agreement, you will need to obtain written permission 
from the copyright owner prior to submission. More information on requesting permission 
to reproduce work(s) under copyright. 
Disclosure statement 
Please include a disclosure of interest statement, using the subheading "Disclosure of 
interest." If you have no interests to declare, please state this (suggested wording: The 
authors report no conflicts of interest). For all NIH/Wellcome-funded papers, the grant 
number(s) must be included in the disclosure of interest statement. Read more on declaring 
conflicts of interest. 
Clinical Trials Registry 
In order to be published in a Taylor & Francis journal, all clinical trials must have been 
registered in a public repository at the beginning of the research process (prior to patient 
enrolment). Trial registration numbers should be included in the abstract, with full details in 
the methods section. The registry should be publicly accessible (at no charge), open to all 
prospective registrants, and managed by a not-for-profit organization. For a list of registries 
that meet these requirements, please visit the WHO International Clinical Trials Registry 
Platform (ICTRP). The registration of all clinical trials facilitates the sharing of information 
among clinicians, researchers, and patients, enhances public confidence in research, and is 
in accordance with the ICMJE guidelines. 
Complying with ethics of experimentation 
Please ensure that all research reported in submitted papers has been conducted in an 
ethical and responsible manner, and is in full compliance with all relevant codes of 
experimentation and legislation. All papers which report in vivo experiments or clinical trials 
on humans or animals must include a written statement in the Methods section. This should 
explain that all work was conducted with the formal approval of the local human subject or 
animal care committees (institutional and national), and that clinical trials have been 
registered as legislation requires. Authors who do not have formal ethics review committees 
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should include a statement that their study follows the principles of the Declaration of 
Helsinki. 
Consent 
All authors are required to follow the ICMJE requirements on privacy and informed consent 
from patients and study participants. Please confirm that any patient, service user, or 
participant (or that person's parent or legal guardian) in any research, experiment, or clinical 
trial described in your paper has given written consent to the inclusion of material 
pertaining to themselves, that they acknowledge that they cannot be identified via the 
paper; and that you have fully anonymized them. Where someone is deceased, please 
ensure you have written consent from the family or estate. Authors may use this Patient 
Consent Form, which should be completed, saved, and sent to the journal if requested. 
Health and safety 
Please confirm that all mandatory laboratory health and safety procedures have been 
complied with in the course of conducting any experimental work reported in your paper. 
Please ensure your paper contains all appropriate warnings on any hazards that may be 
involved in carrying out the experiments or procedures you have described, or that may be 
involved in instructions, materials, or formulae. 
Please include all relevant safety precautions; and cite any accepted standard or code of 
practice. Authors working in animal science may find it useful to consult the International 
Association of Veterinary Editors' Consensus Author Guidelines on Animal Ethics and 
Welfareand Guidelines for the Treatment of Animals in Behavioural Research and Teaching. 
When a product has not yet been approved by an appropriate regulatory body for the use 
described in your paper, please specify this, or that the product is still investigational. 
 
